Company profile
Trevarx Biomedical, Inc.
Discovering and developing radiopharmaceutical platforms that turn deadly diseases into manageable conditions
- Industry
- Biotechnology Research
- Employees
- 2
- Headquarters
- Philadelphia, Pennsylvania
- Founded
- 2016
- LinkedIn followers
- 173
- Office locations
- 1
Trevarx Biomedical, Inc. company summary
Trevarx Biomedical, Inc. is a company in the Biotechnology Research industry, headquartered in Philadelphia, Pennsylvania, founded in 2016. On LinkedIn the company has around 2 employees and 173 followers.
What technology does Trevarx Biomedical, Inc. use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Trevarx Biomedical, Inc.
Trevarx develops small molecule radiopharmaceutical platforms focusing on oncology. Its first platform is a PARP inhibitor (PARPi) analogue with an α-emitting radioligand therapy [211At]PTT (currently in pre-clinical stage) with published proof of concept in neuroblastoma seeking additional indications in adult PARP-1 tumors. Trevarx's PARPi platform has a companion PET biomarker [18F]FTT (entering Phase 2 Multi-Center trials in breast cancer in Spring 2022, led by MD Anderson Cancer Center).
Where is Trevarx Biomedical, Inc. located?
Trevarx Biomedical, Inc. lists 1 location.
Compare companies similar to Trevarx Biomedical, Inc.
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Trevarx Biomedical, Inc. trevarx.com | Biotechnology Research | 2 | 2016 | Philadelphia, Pennsylvania |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Trevarx Biomedical, Inc.
What does Trevarx Biomedical, Inc. do?
Trevarx develops small molecule radiopharmaceutical platforms focusing on oncology. Its first platform is a PARP inhibitor (PARPi) analogue with an α-emitting radioligand therapy [211At]PTT (currently in pre-clinical stage) with published proof of concept in neuroblastoma seeking additional indications in adult PARP-1 tumors. Trevarx's PARPi platform has a companion PET biomarker [18F]FTT (entering Phase 2 Multi-Center trials in breast cancer in Spring 2022, led by MD Anderson Cancer Center).
How many employees does Trevarx Biomedical, Inc. have?
Trevarx Biomedical, Inc. has around 2 employees on LinkedIn.
Where is Trevarx Biomedical, Inc. headquartered?
Trevarx Biomedical, Inc. is headquartered in Philadelphia, Pennsylvania.
When was Trevarx Biomedical, Inc. founded?
Trevarx Biomedical, Inc. was founded in 2016.
Build a lead list from companies like Trevarx Biomedical, Inc.
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.